Regulus Therapeutics, Inc. (RGLS) Company Long-Term Loans and Borrowings

Brandmark of Regulus Therapeutics Inc (RGLS)

This chart illustrates the long-term debt of Regulus Therapeutics (RGLS), which currently stands at 0.00. The business relies on the development of unique RNA-based drugs to combat polycystic kidney disease, anticipating high margins due to the specific nature of the therapy. Stable management effectively adjusts the research plan, attracting capital from specialized funds. Leading geneticists are developing the project, provided with competitive compensation and the necessary resources for scientific activity.

RGLS Regulus Therapeutics: Company Long-Term Debts in the range 07/04/2022 - 07/05/2025

Summary analytical data breakdowns for Regulus Therapeutics Inc (RGLS)

- price and consensus price forecast:
Stock Price regulusrx.com|RGLS - Price Target Chart
- market capitalization data:
Market Value Regulus Therapeutics|RGLS - Enterprise Value
- book capitalization data:
Net Asset Value per Share Regulus Therapeutics|RGLS - Book Capitalization|Market Value to Equity Ratio regulusrx.com|RGLS - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Regulus Therapeutics|RGLS - Long-Term Debt to Equity|Short-Term Debt to Equity Regulus|RGLS - Company Total Debt|Debts to Book Capitalization Regulus Therapeutics|RGLS - Company Long-Term Debt|Short-Term Debt Volume Regulus Therapeutics
Summary company analytics:regulusrx.com (RGLS)
Manufactured products of Regulus

Investors must balance capital protection against volatility with the use of financial leverage. The partnership of Regulus Therapeutics (RGLS) with pharmaceutical behemoths in the field of RNA therapeutics mitigates biological risks, thereby stabilizing the financial profile. The volume of the corporation's long-term loans and borrowings accumulates all multi-year obligations, eliminating gaps between reporting periods. An increase in this metric signals balance sheet pressure, while a decrease indicates a conservative approach. Monitoring this metric allows for an assessment of the company's resilience to credit overheating.

Competing companies

Tempus Labs - Company Long-Term Debts|Company Long-Term Debt Qiagen (QGEN)|IONS - Company Long-Term Loans and Borrowings|Company Long-Term Debts RGEN|Avidity Corp (RNA) - Long-Term Debt|CRISPR Therapeutics AG - Company Long-Term Debts|Long-Term Indebtedness genedx.com (WGS)|Company Long-Term Liabilities RARE|Company Long-Term Debts BEAM (Beam Therapeutics Inc)|Company Long-Term Debt Sarepta Therapeutics Inc SRPT|TWST - Company Long-Term Debt|10x Genomics, Inc. - Company Long-Term Liabilities|NTLA: Company Long-Term Debts|Stoke Therapeutics, Inc. - Company Long-Term Debt|Long-Term Debt Volume BioLife Solutions Inc|WVE - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings Maze Therapeutics Corp (MAZE)|Company Long-Term Liabilities Sionna Therapeutics Inc|Amount of Long-Term Liabilities primemedicine.com (PRME)|Company Long-Term Debts Taysha Gene Therapies, Inc.|Company Long-Term Loans and Borrowings uniQure NV QURE|MGTX (MeiraGTx PLC) - Company Long-Term Debts|RGNX: Long-Term Debt|Company Long-Term Debt Solid Biosciences Inc. SLDB|ocugen.com (OCGN) - Company Long-Term Loans and Borrowings|PACB (PacBio) - Company Long-Term Debts|Company Long-Term Debts BNTC|DSGN - Company Long-Term Debt|Long-Term Liabilities Rocket Corp (RCKT)|FDMT: Company Long-Term Debts|LXEO - Long-Term Debt|Korro Bio, Inc - Company Long-Term Liabilities|Editas Medicine Inc (EDIT) - Company Long-Term Debts|SLN - Company Long-Term Liabilities|ProQR Therapeutics (PRQR) - Amount of Long-Term Liabilities|CDXS: Company Long-Term Debts|Long-Term Debt Volume sangamo.com|Company Long-Term Debts NAUT (Nautilus Biotechnology)|Company Long-Term Liabilities MGX (Metagenomi Inc.)|Company Long-Term Debt DTIL|Generation Bio Co - Long-Term Debt Volume|Company Long-Term Debt Boundless Bio, Inc. (BOLD)|XCUR - Company Long-Term Loans and Borrowings|Company Long-Term Debts IMNN (imunon.com)|PHIO (Phio Pharmaceuticals Corp.) - Long-Term Indebtedness|Company Long-Term Debt Mustang Bio Inc|Company Long-Term Debt RNAZ|BNGO (Bionano Genomics, Inc.) - Company Long-Term Debt|Long-Term Debt Volume adnas.com (APDN)|BLUE - Company Long-Term Debts|ImmunoPrecise Antibodies Ltd - Company Long-Term Indebtedness|Omega (OMGA) - Company Long-Term Debt|OMIC - Company Long-Term Indebtedness|SYRS: Company Long-Term Debts|TBIO (telesisbio.com) - Company Long-Term Debts|TCON - Company Long-Term Debt|Company Long-Term Loans and Borrowings Unity Biotechnology Inc.